AlphaCentric Advisors LLC Buys New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

AlphaCentric Advisors LLC purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,965 shares of the company’s stock, valued at approximately $161,000.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. bought a new stake in Vaxcyte in the 3rd quarter worth approximately $92,000. Signaturefd LLC raised its holdings in shares of Vaxcyte by 51.9% during the 3rd quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after acquiring an additional 358 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Vaxcyte during the 3rd quarter valued at approximately $174,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price target on shares of Vaxcyte in a research note on Tuesday, February 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $127.71.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the sale, the chief executive officer now owns 136,215 shares in the company, valued at $12,565,833.75. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $19,024,730.55. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,616 shares of company stock valued at $6,095,681 over the last 90 days. Insiders own 3.10% of the company’s stock.

Vaxcyte Trading Up 0.2 %

Vaxcyte stock opened at $84.00 on Tuesday. The firm has a market capitalization of $10.47 billion, a PE ratio of -18.26 and a beta of 0.98. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The firm has a 50-day moving average price of $86.19 and a 200-day moving average price of $94.68.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.